Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms-Reference-Cited by-同舟云学术

Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms

Published:2020-10-20 Issue:13 Volume:21 Page:1286-1292
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

Giunchi Francesca¹,Gevaert Thomas²,Scarpelli Marina³,Fiorentino Michelangelo⁴^ORCID

Affiliation:

1. Department of Pathology S.Orsola-Malpighi Hospital, University of Bologna, Italy

2. Department of Development and Regeneration, University of Leuven, Leuven, Belgium

3. Department of Pathology University of Ancona, Italy

4. Department of Pathology Maggiore Hospital, University of Bologna, Italy

Abstract

The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors.

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Reference33 articles.

1. Sharpe A.H.; Pauken K.E.; The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2018,18(3),153-167

2. Pardoll D.M.; The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012,12(4),252-264

3. Patel S.P.; Kurzrock R.; PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015,14(4),847-856

4. Morgensztern D.; KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49. J Thorac Dis 2019,11(Suppl. 15),S1963-S1965

5. Shafique M.R.; Robinson L.A.; Antonia S.; Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res 2018,10,931-940

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD68 positive and/or CD163 positive tumor-associated macrophages and PD-L1 expression in breast phyllodes tumor;Breast Cancer Research and Treatment;2024-09-06

2. Biomarker Expression and Clinical Outcomes in International Study of Chemoradiation and Magnetic Resonance Imaging-Based Image-Guided Brachytherapy for Locally Advanced Cervical Cancer: BIOEMBRACE;International Journal of Radiation Oncology*Biology*Physics;2024-07

3. Digital Pathology Applications for PD-L1 Scoring in Head and Neck Squamous Cell Carcinoma: A Challenging Series;Journal of Clinical Medicine;2024-02-22

4. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores;Human Pathology;2024-02

5. Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2023-09